Cover Image

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis

Background Data are conflicting regarding the possible effects of statins in patients with idiopathic pulmonary fibrosis (IPF). This post hoc analysis assessed the effects of statin therapy on disease-related outcomes in IPF. Methods Patients randomised to placebo (n=624) in three controlled trials...

Full description

Saved in:
Bibliographic Details
Main Author: Kreuter, Michael (Author)
Format: Article (Journal)
Language:English
Published: 2017
In: Thorax
Year: 2016, Volume: 72, Issue: 2, Pages: 148-153
ISSN:1468-3296
DOI:10.1136/thoraxjnl-2016-208819
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1136/thoraxjnl-2016-208819
Verlag, kostenfrei, Volltext: http://thorax.bmj.com/content/72/2/148
Get full text
Author Notes:Michael Kreuter, Francesco Bonella, Toby M. Maher, Ulrich Costabel, Paolo Spagnolo, Derek Weycker, Klaus-Uwe Kirchgaessler, Martin Kolb
Description
Summary:Background Data are conflicting regarding the possible effects of statins in patients with idiopathic pulmonary fibrosis (IPF). This post hoc analysis assessed the effects of statin therapy on disease-related outcomes in IPF. Methods Patients randomised to placebo (n=624) in three controlled trials of pirfenidone in IPF (CAPACITY 004 and 006, ASCEND) were categorised by baseline statin use. Outcomes assessed during the 1-year follow-up included disease progression, mortality, hospitalisation and composite outcomes of death or ≥10% absolute decline in FVC and death or ≥50 m decline in 6-minute walk distance (6MWD). Results At baseline, 276 (44%) patients were statin users versus 348 (56%) non-users. Baseline characteristics were similar between groups, except statin users were older and had higher prevalence of cardiovascular disease and risk factors. In multivariate analyses adjusting for differences in baseline characteristics, statin users had lower risks of death or 6MWD decline (HR 0.69; 95% CI 0.48 to 0.99, p=0.0465), all-cause hospitalisation (HR 0.58; 95% CI 0.35 to 0.94, p=0.0289), respiratory-related hospitalisation (HR 0.44; 95% CI 0.25 to 0.80, p=0.0063) and IPF-related mortality (HR 0.36; 95% CI 0.14 to 0.95, p=0.0393) versus non-users. Non-significant treatment effects favouring statin use were observed for disease progression (HR 0.75; 95% CI 0.52 to 1.07, p=0.1135), all-cause mortality (HR 0.54; 95% CI 0.24 to 1.21, p=0.1369) and death or FVC decline (HR 0.71; 95% CI 0.48 to 1.07, p=0.1032). Conclusions This post hoc analysis supports the hypothesis that statins may have a beneficial effect on clinical outcomes in IPF. Prospective clinical trials are required to validate these observations. Trial registration numbers NCT01366209, NCT00287729 and NCT00287716.
Item Description:First published October 5, 2016
Gesehen am 06.06.2018
Physical Description:Online Resource
ISSN:1468-3296
DOI:10.1136/thoraxjnl-2016-208819

Similar Items